1. Preface
1.1 Table of Contents 2
1.2 Abbreviations 4
1.3 Related Reports 9
1.4 Upcoming Related Reports 10

2. Executive Summary 11
2.1 Key Findings 12
2.2 KOL Insight on Cancer Gene Therapy Competitive Landscape 13

3. Overview - Cancer Gene Therapy 14
3.1 What is Gene Therapy? 16
3.2 Gene Transfer Methods and Vectors Used for Gene Therapy 24
3.3 Viral Vectors 25
3.4 Non-Viral Vectors 31
3.5 Gene Therapy Strategies Employed in Oncology 38
3.6 Sources 56

4. Cancer Gene Therapy in the 8MM 58
4.1 Global Regulatory Agencies’ Definitions of Gene Therapy 59
4.2 Cancer Gene Therapy in the US 60
4.3 Cancer Gene Therapy in the EU 61
4.4 Cancer Gene Therapy in Japan 62
4.5 Cancer Gene Therapy in China 64
4.6 Timeline of Clinical Development in Gene Therapy in the 8MM 65
4.7 Currently Marketed Gene Therapies in Oncology 73
4.8 Sources 80

5. Pipeline Assessment in the 8MM 82
5.1 Cancer Gene Therapy Pipeline in the 8MM 83
5.2 Pipeline Products - Phase III 85
5.3 Pipeline Products - Phase II 86
5.4 Mologen’s Lefitolimod 91
5.5 Idera’s IMO-2125 92
5.6 Geron’s Imetelstat 93
5.7 Oncotelic’s Trabedersen 94
5.8 VBL Therapeutics’ VB-111 95
5.9 Sillajen’s JX-594 97
5.10 Tocagen’s Toca 511 98
5.11 Advantagene’s ProstAtak 100
5.12 MarsalaBiotech’s E-10A 101
5.13 Advaxis’ AXAL 102
5.14 Sources 109

6. Clinical Trials Mapping and Design 110
6.1 Clinical Trial Mapping of Late Stage Gene Therapy Pipeline 112
6.2 Clinical Trial Mapping by Tumor Type 114
6.3 Clinical Trial Duration by Indication 116
6.4 Combination Partner by Therapy Area 122
6.5 Ongoing Clinical Trials of Cancer Gene Therapy Pipeline 123
6.6 Summary 126

7. Payer Perspective on Cancer Gene Therapies 127
7.1 Current Oncology Space 129
7.2 Challenges Associated with Reimbursement of Novel Cancer Therapies 130
7.3 Strategies to Tackle the Cost of Cancer Gene Therapies 131
7.4 A Novel Mechanism to Cover the Cost of Cancer Gene Therapies 132

8. Market Outlook 133
8.1 Phase III Cancer Gene Therapy Pipeline 135
8.2 Key Launch Dates for Phase III and II Cancer Gene Therapy Pipeline 137

9. Appendix 138
9.1 Methodology 139
9.2 Primary Research 140
9.3 About the Authors 141
9.4 About GlobalData 143
9.5 Contact Us 144
9.6 Disclaimer 145

Companies Mentioned
- Advantage
- Advaxis Immunotherapies
- Amgen
- Ascend Biopharmaceuticals
- AstraZeneca
- Bio-Path Holdings
- Bristol-Myers Squibb
- Cold Genesys
- CRISPR Therapeutics
- Daiichi Sankyo
- DNAtrix
- Editas Medicine
- Geron Corp
- Idera Pharmaceuticals
- Intellia Therapeutics
- Johnson & Johnson
- Marsala Biotech
- Merck & Co
- Mologen AG
- MTG Biotherapeutics
- Oncolytics Biotech
- Oncosec
- Oncotelic
- Shanghai Sunway Biotech
- Shenzhen SiBiono GeneTech
- Silenseed
- Sillajen Biotherapeutics
- SynerGene Therapeutics
- Takara Holdings
- Targovax
- Tocagen
- UniQure
- Vascular Biogenics
- Ziopharm Oncology